AACR taking applications for SU2C-Cancer Research UK Fellowship

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE AMERICAN ASSOCIATION FOR CANCER RESEARCH is now accepting applications for the Stand Up To Cancer-Cancer Research U.K. Translational Research Fellowship, which will provide up to four grants for postdoctoral or clinical research fellows, each up to $315,000, over a four-year period.

This grant opportunity is provided by SU2C and Cancer Research U.K. and is the first joint research project resulting from the collaboration between the two groups announced in 2012.

The fellowship will provide four years of research support to early-career investigators in the U.S. and U.K. Research projects must be translational in nature and address critical problems in cancer with the potential to deliver benefit to patients.

The proposed work must be performed in two phases, one in the U.S. and one in the U.K. Each phase must be one to three years in length, and the total support period for this fellowship is a maximum of four years.

Project proposals are due by noon ET July 28, via proposalCENTRAL.

For general information on eligibility criteria, the application process, and other details about this grant, visit the AACR website.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login